News
PHVS
31.25
+4.34%
1.30
Pharvaris Extends Cash Runway Into 2028 as Deucrictibant Nears Key Late-Stage Milestones
TipRanks · 55m ago
Switzerland's Pharvaris Q1 loss per share narrows
Reuters · 1h ago
Pharvaris Raises $124 Million in May Equity Offering to Fund Late-Stage Programs and U.S. Commercial Build-Out
TipRanks · 1d ago
Pharvaris Chief Medical Officer Sells 14,000 Shares for $427,000
The Motley Fool · 1d ago
Pharvaris closes follow-on offering, raises $132.3 million gross proceeds
PUBT · 1d ago
Pharvaris Reports Earnings Days After Pricing a Hundred Million Dollar Offering
Barchart · 1d ago
Pharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Barchart · 1d ago
Weekly Report: what happened at PHVS last week (0504-0508)?
Weekly Report · 1d ago
Pharvaris price target raised to $31 from $30 at BofA
TipRanks · 2d ago
Analysts Offer Insights on Healthcare Companies: Amylyx Pharmaceuticals Inc (AMLX), BioAge Labs, Inc. (BIOA) and Pharvaris (PHVS)
TipRanks · 2d ago
The Bull Case For Pharvaris (PHVS) Could Change Following Dilutive US$115 Million Equity Raise - Learn Why
Simply Wall St · 3d ago
Pharvaris prices $115M stock offering
Seeking Alpha · 4d ago
Pharvaris Prices Underwritten Offering Of 3,874,664 Shares At $29.68 Per Share
Benzinga · 4d ago
Pharvaris prices $115 million follow-on offering at $29.68 per share
PUBT · 4d ago
PHARVARIS NV: PRICING OF AN UNDERWRITTEN OFFERING OF 3,874,664 OF ITS ORDINARY SHARES AT A PRICE OF $29.68 PER SHARE
Reuters · 4d ago
Pharvaris Announces Pricing of $115 Million Underwritten Offering of Ordinary Shares
Barchart · 4d ago
Pharvaris CMO Lu Peng disposes of shares worth $427,111.81
PUBT · 05/05 19:52
Weekly Report: what happened at PHVS last week (0427-0501)?
Weekly Report · 05/04 09:03
Should New Deucrictibant Data on Dual HAE Use Require Action From Pharvaris (PHVS) Investors?
Simply Wall St · 05/02 16:38
Pharvaris Chief Early Development Anne Lesage disposes of shares worth $1.32 million
PUBT · 05/01 23:31
More
Webull provides a variety of real-time PHVS stock news. You can receive the latest news about Pharvaris N.V. through multiple platforms. This information may help you make smarter investment decisions.
About PHVS
Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.